Immunosuppressive Treatment for Nephrotic Idiopathic Membranous Nephropathy: A Meta-Analysis Based on Chinese Adults
Authors:
Open Access
- 5 September 2012
- journal article
- research article
- Published by Public Library of Science (PLoS) in PLOS ONE
- Vol. 7 (9) , e44330
Abstract
Idiopathic membranous nephropathy (IMN) is the most common pathological type for nephrotic syndrome in adults in western countries and China. The benefits and harms of immunosuppressive treatment in IMN remain controversial. To assess the efficacy and safety of different immunosuppressive agents in the treatment of nephrotic syndrome caused by IMN. PubMed, EMBASE, Cochrane Library and wanfang, weipu, qinghuatongfang, were searched for relevant studies published before December 2011. Reference lists of nephrology textbooks, review articles were checked. A meta-analysis of randomized controlled trials (RCTs) meeting the criteria was performed using Review Manager. 17 studies were included, involving 696 patients. Calcineurin inhibitors had a better effect when compared to alkylating agents, on complete remission (RR 1.61, 95% CI 1.13, to 2.30 P = 0.008), partial or complete remission (effective) (CR/PR, RR 1.29, 95% CI 1.09 to 1.52 P = 0.003), and fewer side effects. Among calcineurin inhibitors, tacrolimus (TAC) was shown statistical significance in inducing more remissions. When compared to cyclophosphamide (CTX), leflunomide (LET) showed no beneficial effect, mycophenolate mofetil (MMF) showed significant beneficial on effectiveness (CR/PR, RR: 1.41, 95% CI 1.16 to 1.72 P = 0.0006) but not significant on complete remission (CR, RR: 1.38, 95% CI 0.89 to 2.13 P = 0.15). This analysis based on Chinese adults and short duration RCTs suggested calcineurin inhibitors, especially TAC, were more effective in proteinuria reduction in IMN with acceptable side effects. Long duration RCTs were needed to confirm the long-term effects of those agents in nephrotic IMN.Keywords
This publication has 16 references indexed in Scilit:
- Implication of global nephrology guidelines in Asia and ‘Asian CKD Best Practice Guidelines’Nephrology, 2010
- Tacrolimus Combined With Corticosteroids in Treatment of Nephrotic Idiopathic Membranous Nephropathy: A Multicenter Randomized Controlled TrialThe American Journal of the Medical Sciences, 2010
- Prospective controlled study on mycophenolate mofetil and prednisolone in the treatment of membranous nephropathy with nephrotic syndromeNephrology, 2007
- A Randomized, Controlled Trial of Steroids and Cyclophosphamide in Adults with Nephrotic Syndrome Caused by Idiopathic Membranous NephropathyJournal of the American Society of Nephrology, 2007
- Tacrolimus monotherapy in membranous nephropathy: A randomized controlled trialKidney International, 2007
- Immunosuppressive treatment for idiopathic membranous nephropathy in adults with nephrotic syndrome2004
- Assessing the quality of reports of randomized clinical trials: Is blinding necessary?Controlled Clinical Trials, 1996
- A 10-year follow-up of a randomized study with methylprednisolone and chlorambucil in membranous nephropathyKidney International, 1995
- A Randomized Trial of Methylprednisolone and Chlorambucil in Idiopathic Membranous NephropathyNew England Journal of Medicine, 1989
- Idiopathic membranous nephropathy: The natural history of untreated patientsKidney International, 1988